ACAN

AmeriCann, Inc.
CAPPED RATING

AmeriCann is a producer of medical cannabis. The company maintains state of the art facilities that create controlled environments to consistently produce a high quality product. They also engage in sustainable cultivation and processing.

AmeriCann, Inc. (ACAN) is rated D+ (1.8/5) on Deltasharpe Prism, scored against General sector peers. Its strongest pillar is Profitability (B); its weakest is Growth (F). The rating has held at D+ for 26 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.8 / 5.0
D+
Value
C+
Factor Score 2.5 / 5.0
Growth
F
Factor Score 0.1 / 5.0
Profitability
B
Factor Score 3.2 / 5.0
Momentum
D+
Factor Score 1.7 / 5.0
Revisions
D+
Factor Score 1.5 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA N/A
Rev Growth YoY -64.5%
Gross Margin 99.3%
Price Return 3M 0.0%
Price Return 12M 0.0%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales N/A
ROE -10.3%

Historical Factor Score Progression

Held D+ for 26 weeks
Date Value Growth Profitability Momentum Revisions Overall
2024-09-30 C+ (2.5) F (0.1) B (3.2) D+ (1.7) D+ (1.5) D+ (1.8)
2024-06-30 C+ (2.5) F (0.2) C+ (2.5) D+ (1.7) D (1.5) D+ (1.7)
2024-03-31 C+ (2.5) D- (0.7) D+ (1.8) D+ (1.7) D+ (1.5) D+ (1.7)
2023-12-31 C+ (2.5) D- (0.9) C+ (2.5) C (2.2) D (1.5) C- (1.9)
2023-09-30 C+ (2.5) F (0.6) B (3.4) C (2.2) D (1.5) C- (2.0)
Page 1 of 4